SANOFI-AVENTIS RECEIVES FDA APPROVAL FOR NEW ELOXATIN® FORMULATION
SANOFI-AVENTIS RECEIVES FDA APPROVAL FOR NEW ELOXATIN® FORMULATION Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians and nurses since it involves fewer steps in the administration of Eloxatin®. For complete press release, se attached file! -------------